Amgen Inc. (AMGN)
AMGN Stock Price Chart
Explore Amgen Inc. interactive price chart. Choose custom timeframes to analyze AMGN price movements and trends.
AMGN Company Profile
Discover essential business fundamentals and corporate details for Amgen Inc. (AMGN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - General
IPO Date
17 Jun 1983
Employees
28.00k
Website
https://www.amgen.comCEO
Robert A. Bradway
Description
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
AMGN Financial Timeline
Browse a chronological timeline of Amgen Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is $5.58, while revenue estimate is $9.43bn.
Dividend declared on 15 May 2026
A dividend of $2.52 per share was announced, adjusted to $2.52. The dividend was paid on 5 Jun 2026.
Earnings released on 30 Apr 2026
EPS came in at $5.15 surpassing the estimated $4.77 by +7.97%, while revenue for the quarter reached $8.62bn , beating expectations by +0.50%.
Dividend declared on 13 Feb 2026
A dividend of $2.52 per share was announced, adjusted to $2.52. The dividend was paid on 6 Mar 2026.
Earnings released on 3 Feb 2026
EPS came in at $5.29 surpassing the estimated $4.73 by +11.84%, while revenue for the quarter reached $9.87bn , beating expectations by +4.14%.
Dividend declared on 21 Nov 2025
A dividend of $2.38 per share was announced, adjusted to $2.38. The dividend was paid on 12 Dec 2025.
Earnings released on 4 Nov 2025
EPS came in at $5.64 surpassing the estimated $5.02 by +12.35%, while revenue for the quarter reached $9.56bn , beating expectations by +6.59%.
Dividend declared on 22 Aug 2025
A dividend of $2.38 per share was announced, adjusted to $2.38. The dividend was paid on 12 Sept 2025.
Earnings released on 5 Aug 2025
EPS came in at $6.02 surpassing the estimated $5.28 by +14.02%, while revenue for the quarter reached $9.17bn , beating expectations by +2.59%.
Dividend declared on 16 May 2025
A dividend of $2.38 per share was announced, adjusted to $2.38. The dividend was paid on 6 Jun 2025.
Earnings released on 1 May 2025
EPS came in at $4.90 surpassing the estimated $4.27 by +14.75%, while revenue for the quarter reached $8.15bn , beating expectations by +1.14%.
Dividend declared on 14 Feb 2025
A dividend of $2.38 per share was announced, adjusted to $2.38. The dividend was paid on 7 Mar 2025.
Earnings released on 4 Feb 2025
EPS came in at $5.31 surpassing the estimated $5.04 by +5.36%, while revenue for the quarter reached $9.09bn , beating expectations by +2.31%.
Dividend declared on 18 Nov 2024
A dividend of $2.25 per share was announced, adjusted to $2.25. The dividend was paid on 9 Dec 2024.
Earnings released on 30 Oct 2024
EPS came in at $5.58 surpassing the estimated $5.11 by +9.20%, while revenue for the quarter reached $8.50bn , beating expectations by +0.06%.
Dividend declared on 16 Aug 2024
A dividend of $2.25 per share was announced, adjusted to $2.25. The dividend was paid on 6 Sept 2024.
Earnings released on 6 Aug 2024
EPS came in at $4.97 falling short of the estimated $4.98 by -0.20%, while revenue for the quarter reached $8.39bn , beating expectations by +0.43%.
Dividend declared on 16 May 2024
A dividend of $2.25 per share was announced, adjusted to $2.25. The dividend was paid on 7 Jun 2024.
Earnings released on 2 May 2024
EPS came in at $3.96 surpassing the estimated $3.88 by +2.06%, while revenue for the quarter reached $7.45bn , missing expectations by -0.06%.
Dividend declared on 15 Feb 2024
A dividend of $2.25 per share was announced, adjusted to $2.25. The dividend was paid on 7 Mar 2024.
Earnings released on 6 Feb 2024
EPS came in at $4.71 surpassing the estimated $4.59 by +2.61%, while revenue for the quarter reached $8.20bn , beating expectations by +0.86%.
Dividend declared on 16 Nov 2023
A dividend of $2.13 per share was announced, adjusted to $2.13. The dividend was paid on 8 Dec 2023.
Earnings released on 31 Oct 2023
EPS came in at $4.96 surpassing the estimated $4.65 by +6.67%, while revenue for the quarter reached $6.90bn , beating expectations by +4.33%.
Dividend declared on 17 Aug 2023
A dividend of $2.13 per share was announced, adjusted to $2.13. The dividend was paid on 8 Sept 2023.
Earnings released on 3 Aug 2023
EPS came in at $5.00 surpassing the estimated $4.44 by +12.61%, while revenue for the quarter reached $6.99bn , beating expectations by +4.64%.
Dividend declared on 17 May 2023
A dividend of $2.13 per share was announced, adjusted to $2.13. The dividend was paid on 8 Jun 2023.
Earnings released on 27 Apr 2023
EPS came in at $3.98 surpassing the estimated $3.85 by +3.38%, while revenue for the quarter reached $6.11bn , missing expectations by -8.17%.
Dividend declared on 14 Feb 2023
A dividend of $2.13 per share was announced, adjusted to $2.13. The dividend was paid on 8 Mar 2023.
Earnings released on 31 Jan 2023
EPS came in at $4.09 surpassing the estimated $4.04 by +1.24%, while revenue for the quarter reached $6.84bn , beating expectations by +1.41%.
Dividend declared on 16 Nov 2022
A dividend of $1.94 per share was announced, adjusted to $1.94. The dividend was paid on 8 Dec 2022.
Earnings released on 3 Nov 2022
EPS came in at $4.70 surpassing the estimated $4.44 by +5.86%, while revenue for the quarter reached $6.65bn , beating expectations by +1.34%.
Dividend declared on 17 Aug 2022
A dividend of $1.94 per share was announced, adjusted to $1.94. The dividend was paid on 8 Sept 2022.
Earnings released on 4 Aug 2022
EPS came in at $4.65 surpassing the estimated $4.40 by +5.68%, while revenue for the quarter reached $6.59bn , beating expectations by +0.96%.
Dividend declared on 16 May 2022
A dividend of $1.94 per share was announced, adjusted to $1.94. The dividend was paid on 8 Jun 2022.
Earnings released on 27 Apr 2022
EPS came in at $4.25 surpassing the estimated $4.22 by +0.71%, while revenue for the quarter reached $6.24bn , beating expectations by +2.78%.
Dividend declared on 14 Feb 2022
A dividend of $1.94 per share was announced, adjusted to $1.94. The dividend was paid on 8 Mar 2022.
Earnings released on 7 Feb 2022
EPS came in at $4.36 surpassing the estimated $4.14 by +5.31%, while revenue for the quarter reached $6.85bn , missing expectations by -0.34%.
Dividend declared on 15 Nov 2021
A dividend of $1.76 per share was announced, adjusted to $1.76. The dividend was paid on 8 Dec 2021.
Earnings released on 2 Nov 2021
EPS came in at $4.67 surpassing the estimated $4.22 by +10.66%, while revenue for the quarter reached $6.71bn , missing expectations by -0.08%.
Dividend declared on 16 Aug 2021
A dividend of $1.76 per share was announced, adjusted to $1.76. The dividend was paid on 8 Sept 2021.
Earnings released on 3 Aug 2021
EPS came in at $4.38 surpassing the estimated $4.13 by +6.05%, while revenue for the quarter reached $6.53bn , beating expectations by +1.18%.
AMGN Stock Performance
Access detailed AMGN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
